Application Note: An Easy-to-Use Assay to Measure Target Cell Death by Antibody Dependent Cellular Phagocytosis (ADCP)
With an increasing industry focus on antibody drugs, there is an ever greater need for functional bioassays that interrogate the various mechanisms of action (MOA) for the therapeutic antibody…
The most common human immunoglobulin isotype used for therapeutic intervention is IgG1, which contains two antigen-binding Fab arms and an Fc region. This Fc domain of IgG1 can bind to Fcγ receptors expressed on immune effector cells and mediate target cell death by various mechanisms such as Complement Dependent Cytotoxicity (CDC), Antibody Dependent Cell-Mediated Cytotoxicity (ADCC), and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP).
Regulatory authorities are now commonly requiring data on the impact of each of these effectormediated MOAs for each submitted antibody therapeutic. There are a number of available ways to measure these effector-mediated MOAs, however getting a reproducible true measure of ADCP, in particular, has been quite challenging.
This Application Note is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Related content from this organisation
- Q&A: Implementing ADCC assays in QC: when donor variability isn’t an option
- Implementing ADCC assays in QC: When donor variability isn’t an option
- Drug Target Review – Issue #3 2017
- Skin toxicity mechanisms associated with mGluR5 negative allosteric modulators
- The mast cell receptor MrgX2 and drug-induced anaphylaxis